戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nocyte chemoattractant protein-1) and VLA-4 (very-late antigen-4).
2 r by chemokines leads to the inactivation of very late antigen 4.
3 tide affinity ligand, VHPKQHR, homologous to very late antigen-4, a known ligand for VCAM-1.
4  lymphocyte adhesion but partially conserved very late antigen-4 adhesiveness.
5 e detected the active conformational form of very late antigen 4 after stimulation with a peptide mim
6                       The leukocyte integrin very late antigen-4 (alpha(4)beta(1), CD49d/CD29) is an
7                        Activated T cells use very late antigen-4/alpha4beta1 integrin for capture, ro
8 irway inflammation and was prevented by anti-very late antigen-4 and anti-interleukin-5 treatments, w
9                                              Very late antigen-4 and CD11/CD18 integrins mediated pas
10 s of beta1 phosphorylation and a decrease in very late antigen 4 binding to its ligand vascular cell
11 imilar to, but more restricted than, current very late antigen-4-directed approaches that have signif
12 and natalizumab (Tysabri/Antegren) targeting very late antigen-4 for the treatment of relapsing-remit
13 ncrease expression of VCAM-1, a receptor for very late antigen-4 found on many hematopoietic progenit
14 dent mechanism to increase CD11c expression, very late antigen-4 function, and integrin coclustering
15 te function-associated antigen-1) and VLA-4 (very late antigen-4) is essential for T-cell trafficking
16 lymphocyte function-associated antigen-1 and very late antigen-4) on splenocytes.
17  for the integrin alpha4beta1 (also known as very late antigen-4 or VLA-4).
18 ction by 50%, whereas blocking L-selectin or very late antigen-4 showed significant but smaller effec
19       The optimization and validation of the very late antigen-4/vascular cell adhesion molecule-1 as
20                                              Very late antigen 4 (VLA-4) and CD11/CD18 integrins medi
21 tes matrix metalloproteinase-9 secretion and very late antigen 4 (VLA-4)-mediated adhesion to vascula
22 e function-associated antigen 1 (LFA-1), and very late antigen 4 (VLA-4).
23 s mediated by a single integrin heterodimer, very late antigen 4 (VLA-4).
24                                         Anti-very late antigen 4 (VLA-4; on neutrophils) inhibited ad
25                       The leukocyte integrin very late antigen-4 (VLA-4) (alpha 4 beta 1, CD49d/CD29)
26 hocytes that expressed low or high levels of very late antigen-4 (VLA-4) and non-antigen-specific act
27 rs to stromal cells is primarily mediated by very late antigen-4 (VLA-4) and vascular cell adhesion m
28                             Extremely potent very late antigen-4 (VLA-4) antagonists with picomolar,
29 nction-associated antigen (LFA-1) and VCAM-1/very late antigen-4 (VLA-4) at select time points compar
30 rsor cells were transiently transfected with very late antigen-4 (VLA-4) binding to vascular cell adh
31                                           As very late antigen-4 (VLA-4) can exist in different funct
32  later, GVHD-associated increase in CD25 and very late antigen-4 (VLA-4) expression on donor T cells
33 lar endothelial growth factor receptor-1 and very late antigen-4 (VLA-4) have been shown to arrive at
34 ell adhesion molecule-1 (VCAM-1), LFA-1, and very late antigen-4 (VLA-4) have relatively little effec
35 esent study was to determine the role of the very late antigen-4 (VLA-4) integrin/ligand interaction
36 te function-associated antigen-1 (LFA-1) and very late antigen-4 (VLA-4) on adhesion of influenza hem
37                            The expression of very late antigen-4 (VLA-4) on the surface of MBP-primed
38 scular cell adhesion molecule 1 (VCAM-1) and very late antigen-4 (VLA-4) played an integral role in t
39                               Interaction of very late antigen-4 (VLA-4) with its ligand vascular cel
40 ion, we show that MBP-primed T cells express very late antigen-4 (VLA-4), and functional blocking ant
41  the adhesion molecules CD11a, CD11b, CD11c, very late antigen-4 (VLA-4), and L-selectin, as assessed
42                The alpha(4)beta(1)-integrin (very late antigen-4 (VLA-4), CD49d/CD29) is an adhesion
43 portance of VCAM-1, and its leukocyte ligand very late antigen-4 (VLA-4), in such leukocyte migration
44                     Natalizumab, which binds very late antigen-4 (VLA-4), is a potent therapy for mul
45 he affinity of the alpha(4)beta(1) integrin, very late antigen-4 (VLA-4), measured with an LDV-contai
46 lasts within the bone marrow is adhesion via very late antigen-4 (VLA-4), the alpha(4)beta(1) integri
47 D49d), in complex with integrin beta1, forms very late antigen-4 (VLA-4), which interacts with vascul
48 cular cell adhesion molecule-1 (VCAM-1)- and very late antigen-4 (VLA-4)-mediated localization of CXC
49 and human monoblastoid U937 cells expressing Very Late Antigen-4 (VLA-4).
50 ascular cell adhesion molecule-1 (VCAM-1) or very late antigen-4 (VLA-4).
51 une cells from patients under long-term anti-very late antigen-4 (VLA-4)/natalizumab therapy (LTNT) a
52  skin fibroblasts, making it unlikely that a very late antigen-4 (VLA-4)/VCAM-1 interaction is requir
53 ion of one of the major leukocyte integrins, very late antigen-4 (VLA-4, CD49d/CD29).
54 duced by IL-3 in a dose-dependent manner via very late antigen-4 (VLA-4; alpha4beta1 integrins) and V
55                                              Very late antigen-4 (VLA-4; also called integrin alpha4b
56 tion of the interaction between the integrin very-late antigen-4 (VLA-4; alpha 4 beta 1) and vascular
57 , a ligand for the alpha(4)beta(1) integrin, very-late-antigen-4 (VLA-4 or CD49d).
58                                              Very-late-antigen-4 (VLA-4, alpha4beta1 integrin, CD49d/
59 elated protein ligand, resulting in enhanced very late antigen-4 [VLA-4] directed adhesion and motili
60                     The antigen alpha4beta1 (very late antigen-4, VLA-4) plays an important role in t
61    To provide further insights into the anti-very late antigen 4 (VLA4)/anti-vascular cell adhesion m
62 ascular cell adhesion molecule-1 (VCAM1) and very late antigen-4 (VLA4) using monoclonal antibodies.
63 cule antagonist, compound A, to nonactivated very late antigen-4 (VLA4) was examined in lung inflamma
64 BL1(+) progenitors had similar expression of very late antigen-4 (VLA4), VLA5, leukocyte functional a
65 al cells, and mild expression of its ligand, very late antigen-4, was apparent in perivascular lympho

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。